One blood transfusion could prevent ventilator setbacks in ICU
NCT ID NCT07499492
First seen Jun 25, 2026 · Last updated Jul 10, 2026 · Updated 3 times
Summary
This study tests whether giving a single unit of red blood cells to high-risk ICU patients right before removing the breathing tube can prevent the need to put the tube back in or reduce deaths within 7 days. The trial plans to enroll 800 adults who have been on a ventilator for at least 24 hours and are at high risk of complications. Half will get the transfusion plus standard care, and half will get standard care alone.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Red blood cell transfusion
- What this could lead to
- If it works, this could provide a simple way to reduce dangerous complications like reintubation in ICU patients being taken off ventilators.
- What could go wrong
- This trial hasn't started yet, and the benefit of transfusion must be weighed against risks like infection or transfusion reactions. Results may not apply to all ICU patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 800 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Sep 2026
An estimate. Start dates often move.
- Expected to finish
-
Dec 2028
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Age ≥ 18 years * Duration of invasive mechanical ventilation prior to extubation ≥ 24h * Planned extubation after weaning trial success * Patients at high risk of reintubation having at least one of the following criteria: older than 65 years, underlying chronic cardiac disease (including: left ventricular ejection fraction ≤ 45%, documented ischemic cardiopathy, chronic supraventricular arrhythmia, history of cardiogenic pulmonary edema) or lung disease (including documented or suspected: chronic obstructive pulmonary disease, obesity-hypoventilation syndrome, or restrictive pulmonary disease) * Haemoglobin level between 7.5 and 9.5 g/dl in the previous 48 hours (with no active bleeding and no transfusion in the interval) * Express informed consent (oral) from the relatives or the patient himself, or emergency inclusion procedure in case of inability of patient or proxy relatives to give consent * Affiliated to social security Exclusion Criteria: * Acute coronary syndrome with ST elevation in the previous 4 weeks * Peripheral neuromuscular disease as reason for intubation (underlying myopathy or myasthenia gravis) * Known objection to the administration of human blood products * Active bleeding * Inclusion in another trial investigating RBC transfusion and/or erythropoietin/ and/or post extubation strategies * Do-not-reintubate order at time of extubation * Vulnerable persons, under the protection of justice * Persons deprived of their liberty by judicial or administrative decision * Persons under legal protection (guardianship, curatorship) * Pregnant or breast-feeding woman
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RBCS transfusion in critically-ill patients are added.
Genom att skicka in godkänner du våra Användarvillkor
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.